IMUNON Announces Strategic Investment in Transomic Technologies
Investment of $375,000 with Senior Convertible Notes and Warrants; Strengthens Development Capabilities for IMUNON’s PLACCINE DNA Vaccine Platform
Related news for (IMNN)
- IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift
- 24/7 Market News Snapshot 22 September, 2025 – Imunon, Inc. Common Stock (NASDAQ:IMNN)
- IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer
- 24/7 Market News Snapshot 30 July, 2025 – Imunon, Inc. Common Stock (NASDAQ:IMNN)
- Don’t Miss Out: MoBot’s Latest Stock Updates 07/17/25 10:00 AM